Skip to main content
Figure 4 | BMC Medical Genomics

Figure 4

From: Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use

Figure 4

A-D: Analysis of bone marrow aspirate specimen variability vs. RNA quality and GEP70 risk score; The relative CD138+ cell content (pre- and post- sorting) vs RNA integrity and GEP70 risk score of 1000 randomly selected clinical specimens submitted for MyPRS analysis is shown above. The wide range in cellularity of specimens submitted for MyPRS analysis (0.25 - 96.2%) does not impact on the quality of the RNA isolated for gene expression profiling, nor the final GEP70 risk score.

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us